Last updated: August 3, 2025
Introduction
Patent RU2011104205, granted in the Russian Federation, pertains to a novel pharmaceutical formulation or method. As the pharmaceutical patent landscape continues to evolve amid international harmonization efforts, understanding the scope, claims, and strategic positioning of this patent is vital for stakeholders involved in drug development, licensing, and patent strategy within Russia.
This article provides an in-depth analysis of RU2011104205, exploring its scope, claims, and positioning within the broader Russian patent landscape, emphasizing its potential impact on competitors, generic entrants, and licensers.
Patent Overview
Patent Number: RU2011104205
Filing Date: Likely in 2011 (based on patent number)
Publication Date: Estimated around 2012-2013
Priority Status: National, with possible international counterparts pending or granted elsewhere
The patent essentially relates to a pharmaceutical composition or process expected to offer a novel therapeutic or manufacturing feature, with aims to improve efficacy, stability, or production efficiency.
Scope and Claims Analysis
Claims Summary
The core legislative and practical power of RU2011104205 lies in its claims. Although precise claim language would be accessible via the official patent documentation, typical claims in such pharmaceutical patents encompass:
- Composition claims: Covering specific molecular combinations or formulations.
- Method claims: Encompassing novel manufacturing processes or therapeutic methods.
- Use claims: Covering new therapeutic uses of known compounds.
- Device or formulation-specific claims: Regarding delivery systems or unique excipient combinations.
In the case of RU2011104205, the claims most likely focus on a specific drug formulation characterized by unique excipient ratios that confer improved stability or bioavailability, or a novel synthesis process that reduces manufacturing costs.
Claim Construction and Limitations
-
Independent Claims: Typically broad, defining the essence of the invention, such as a pharmaceutical composition comprising specific active ingredients and particular excipients.
-
Dependent Claims: Narrower, refining the scope by adding specific features, such as specific concentration ranges or additional components.
Key considerations:
- The breadth of independent claims determines the patent's territorial scope.
- Narrow claims limit infringement but can be easier to defend.
- Broader claims maximize exclusivity but are more susceptible to invalidation via prior art.
For RU2011104205, the claims are probably crafted to balance broad protection of the chemical entity or process with specific features that distinguish it from prior art.
Patent Landscape Context
Russian Pharmaceutical Patent Environment
Russia adheres to national law aligned with the Eurasian Patent Convention and is influenced by the TRIPS Agreement. The reverse-engineering of existing drugs is common, but innovation patents like RU2011104205 benefit from the significant legal framework supporting inventive steps.
Key features in Russian pharmaceutical patents:
- Patent Term: Usually 20 years from the filing date, subject to annual maintenance fees.
- Patentability Criteria: Novelty, inventive step, and industrial applicability.
- Data Exclusivity: Often aligned with patent rights; data protection can extend 5-10 years.
Comparative Patent Landscape
In the Russian context, RU2011104205 sits within a competitive patent ecosystem involving:
- Other national patents for similar compounds or formulations.
- International patents filed via WIPO or EPO, possibly with Russian counterparts.
- Patent applications published but not granted, which may impact freedom-to-operate assessments.
The positioning of RU2011104205 hinges on its novelty over existing patents, and any similarities with prior art could challenge its validity.
Prior Art References and Potential Challenges
Prior art may include:
- Existing formulations or synthesis methods disclosed in Russian or global patent filings.
- Publication databases detailing similar compounds or processes.
- Use of known drugs in new formulations with novel excipients or delivery systems.
Challengers could target claims that lack inventive step if similar formulations exist, especially considering existing Russian or Eurasian patents.
Strategic Considerations
-
Freedom-to-Operate:
The patent's breadth and claim scope determine whether competitors can develop generic versions or alternative formulations without infringement.
-
Patent Life and Maintenance:
Ensuring the patent’s validity is maintained, especially since pharmaceutical patents face specific term and exclusivity issues.
-
Litigation and Enforcement:
The Russian legal framework offers mechanisms for patent infringement enforcement, critical for protecting rights embedded in RU2011104205.
-
Potential for Licensing or Collaboration:
If the patent covers a valuable therapeutic niche, licensing negotiations could be lucrative—especially if the patent owner holds rights to an innovative drug delivery system.
Implications for the Russian Patent Landscape
RU2011104205 symbolizes Russia’s efforts to foster local pharmaceutical innovation. Its strategic positioning influences:
- Encouragement of innovative pharmaceutical R&D.
- Protection of early-stage drug development.
- Inhibition of illegitimate generic entry, provided claims are sufficiently broad and enforceable.
It also contributes to the dynamic of patent thickets that can complicate market entry for challengers.
Key Takeaways
-
Claims Scope:
While specific claim language is critical, RU2011104205 likely encompasses both composition and process claims tailored to a particular pharmaceutical formulation or manufacturing method.
-
Patent Strategy:
The patent’s strength relies on its novelty, inventive step, and claim breadth. It’s advisable for competitors to scrutinize prior art for potential overlaps.
-
Landscape Position:
The patent aligns with Russia’s national innovation goals, serving as a barrier to entry for generic competitors and as leverage in licensing negotiations.
-
Legal and Commercial Viability:
Ongoing patent enforcement and strategic management are essential, especially as patent life progresses and market competition intensifies.
FAQs
Q1: What makes RU2011104205 distinct from other pharmaceutical patents in Russia?
Its claims likely define a unique formulation or synthesis process not previously disclosed, giving it legal exclusivity within Russia for those specific innovations.
Q2: How does the Russian patent landscape influence the enforceability of RU2011104205?
Russian law provides mechanisms for patent enforcement; however, validity depends on maintaining the patent's novelty and inventive step against prior art challenges.
Q3: Can generic companies bypass RU2011104205?
Only if they develop substantially different formulations, processes, or use alternative active ingredients not covered by the claims. Narrower or invalid claims could be circumvented.
Q4: What is the strategic importance of this patent for pharmaceutical companies?
It secures exclusive rights within Russia, allowing the patent holder to recover R&D investments and negotiate licensing or strategic partnerships.
Q5: Is RU2011104205 enforceable beyond Russia?
No, unless counterparts are filed and granted via regional or international patent systems such as Eurasian or WIPO, respectively.
References
[1] Russian Patent Office (FIPS). Official patent document for RU2011104205.
[2] Eurasian Patent Office. Guidelines for patent examination and landscape considerations.
[3] World Intellectual Property Organization (WIPO). Patent databases and prior art search tools.
[4] Russian Civil Code, Part IV. Patent law applicable in Russia.
[5] Regional pharmaceutical patent landscape reports, 2022.
